Skip to main content
The Morning Star Shop
Corbyn's failed leadership challenger Owen Smith returns to career in big pharma
Owen Smith and Jeremy Corbyn before the announcement of the winner in the Labour leadership contest in 2016

FORMER MP and failed challenger for the Labour leadership Owen Smith has returned to working for a big pharma firm, according to an update on his LinkedIn profile.

Mr Smith, who was instrumental in launching a failed coup against Jeremy Corbyn’s leadership in 2016, has been appointed as executive director of market access and external affairs for drugs firm Bristol Myers Squibb.

Mr Smith’s profile on the popular employment networking site also lists his bid for the Labour leadership as part of his political past.

Mr Corbyn took 62 per cent of the vote against Mr Smith and remained leader for four more years.

Before being elected to Parliament in 2010 to represent Pontypridd, Mr Smith was a lobbyist and director for pharma giant Pfizer before moving on to become a director at scandal-hit drugs firm Amgen.

While at Pfizer he oversaw a controversial deal in which the firm appointed Alliance-Unichem as its sole distributor in Britain — bypassing wholesalers in a “direct-to-pharmacy” deal that removed opportunities for cost-cutting competition.

Mr Smith also argued for the interests of big pharma while an MP. In a parliamentary debate in 2010 he warned that the government must be “careful” about advocating for certain generic drugs, which are used to save the NHS money.

The 95th Anniversary Appeal
Support the Morning Star
You have reached the free limit.
Subscribe to continue reading.
Similar stories
Prime Minister Sir Keir Starmer speaks to guests as he hosts
Features / 24 January 2025
24 January 2025
SOLOMON HUGHES reports on how a mega-wealthy hedge fund manager is dishing out cash to a ‘cringe’ Labour Party mediocrity with contempt for the voters
QUO VADIS? James Lyons He made friends with the Labour right
Features / 24 October 2024
24 October 2024
By hiring a former TikTok PR man as its new head of comms, Labour shows that corporate wheeling and dealing rather than principled politics will be the party’s priority, says SOLOMON HUGHES
An electron micrograph of HIV-1 virus particles (colourized
Features / 13 September 2024
13 September 2024
ALAN ROSSI SILVA argues that Gilead’s HIV prevention drug, while promising, highlights systemic failures in the pharmaceutical industry, showing the need to shift towards state-owned drug development and production